Bruce Richard Hill, LVN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 1229 Palomino Rd, Fallbrook, CA 92028 Phone: 760-803-3076 |
Mellisa Covarrubias, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 127 N Stage Coach Ln, Fallbrook, CA 92028 Phone: 760-421-8151 |
Cameron Cardona, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 624 E Elder St, Fallbrook, CA 92028 Phone: 760-451-4165 |
Ms. Pat Byrnes, LVN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 1742 Macadamia Dr, Fallbrook, CA 92028 Phone: 949-615-9065 |
Brandy Lewis, LVN, DSD Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 624 E Elder St, Fallbrook, CA 92028 Phone: 760-451-4165 |
Phyllis Hurt, LVN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 214 Calle De La Paloma, Fallbrook, CA 92028 Phone: 760-689-8589 |
News Archive
A research team supported by the National Institutes of Health (NIH) Roadmap and the National Institute of Allergy and Infectious Diseases (NIAID) has identified chemical compounds that hold promise as potential therapies for schistosomiasis, a parasitic disease that afflicts more than 200 million people worldwide.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.
Arizona State University's Biodesign Institute- has announced a partnership with Life Technologies Corporation as it enters the next phase of a multi-million-dollar, multi-institutional research project to develop a medical device to rapidly assess an individual's exposure to radiation in the event of a nuclear incident.
Researchers say that women who have an abortion can suffer mental distress, anxiety, guilt and shame for years afterwards.
Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.
› Verified 2 days ago